Return to Article Details Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure Download Download PDF